Alteplase treatment does not increase brain injury after mechanical middle cerebral artery occlusion in the rat

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 11, 2013, Pages

  Sutherland, Brad A ^a   Buchan, Alastair M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

alteplase; cerebral ischemia; infarct; L arginine; middle cerebral artery occlusion; recombinant tissue plasminogen activator

Indexed keywords

ALTEPLASE; ARGININE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN INJURY; BRAIN ISCHEMIA; DRUG EFFECT; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE PATIENT; WISTAR RAT;

ANIMALS; ARGININE; BRAIN; CEREBRAL HEMORRHAGE; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FIBRINOLYTIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; RATS; RATS, WISTAR; SURVIVAL ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84887088804     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.148     Document Type: Article

References (32)

1. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981; 46: 561-565. (Pubitemid 11049531)
2. NINDS. Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-pa stroke study group. N Engl J Med 1995; 333: 1581-1587.
3. Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N et al. Stroke treatment with alteplase given 3.0-4.5 hours after onset of acute ischaemic stroke (ecass iii): Additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 2009; 8: 1095-1102.
4. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP et al. Association of outcome with early stroke treatment: pooled analysis of atlantis, ecass, and ninds rt-pa stroke trials. Lancet 2004; 363: 768-774.
5. Harston GW, Sutherland BA, Kennedy J, Buchan AM. The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: A review of rtpa neurotoxicity. J Cereb Blood Flow Metab 2010; 30: 1804-1816.
6. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004; 24: 945-963. (Pubitemid 39223619)
7. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tpa) increases neuronal damage after focal cerebral ischemia in wild-type and tpa-deficient mice. Nat Med 1998; 4: 228-231. (Pubitemid 28138083)
8. Klein GM, Li H, Sun P, Buchan AM. Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology 1999; 52: 1381-1384. (Pubitemid 29190527)
9. Meng W, Wang X, Asahi M, Kano T, Asahi K, Ackerman RH et al. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1999; 19: 1316-1321. (Pubitemid 30013622)
10. Nguyen TH, Ward C. Stability characterization and formulation development of alteplase, a recombinant tissue plasminogen activator. In: Wang YJ, Pearlman R (eds). Stability and CharActerization of Protein and Peptide Drugs: Case Histories. Plenum Press: New York, 1993, pp 91-134.
11. Palmer RM, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988; 153: 1251-1256.
12. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997; 20: 132-139. (Pubitemid 27086729)
13. Nagel S, Papadakis M, Chen R, Hoyte LC, Brooks KJ, Gallichan D et al. Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2011; 31: 132-143.
14. Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 1995; 26: 627-634, discussion 635.
15. Hossmann KA. Periinfarct depolarizations. Cerebrovasc Brain Metab Rev 1996; 8: 195-208.
16. Strong AJ, Anderson PJ, Watts HR, Virley DJ, Lloyd A, Irving EA et al. Peri-infarct depolarizations lead to loss of perfusion in ischaemic gyrencephalic cerebral cortex. Brain 2007; 130: 995-1008. (Pubitemid 47355590)
17. Hartings JA, Rolli ML, Lu XC, Tortella FC. Delayed secondary phase of peri-infarct depolarizations after focal cerebral ischemia: Relation to infarct growth and neuroprotection. J Neurosci 2003; 23: 11602-11610. (Pubitemid 38021287)
18. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379: 2364-2372.
19. Balami JS, Sutherland BA, Buchan AM. Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke. CNS Neurol Disord Drug Targets 2013; 12: 155-169.
20. Kidwell CS, Latour L, Saver JL, Alger JR, Starkman S, Duckwiler G et al. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008; 25: 338-343. (Pubitemid 351555857)
21. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J et al. Activation of pdgfcc by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14: 731-737.
22. Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 2009; 29: 715-725.
23. Kilic E, Bahr M, Hermann DM. Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke 2001; 32: 2641-2647. (Pubitemid 33055319)
24. Kilic E, Kilic U, Matter CM, Luscher TF, Bassetti CL, Hermann DM. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor but does not depend on endothelial no synthase. Stroke 2005; 36: 332-336. (Pubitemid 40170818)
25. Cipolla MJ, Lessov N, Clark WM, Haley Jr. EC. Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator. Stroke 2000; 31: 940-945. (Pubitemid 30198443)
26. Nassar T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M et al. In vitro and in vivo effects of tpa and pai-1 on blood vessel tone. Blood 2004; 103: 897-902. (Pubitemid 38129548)
27. Park L, Gallo EF, Anrather J, Wang G, Norris EH, Paul J et al. Key role of tissue plasminogen activator in neurovascular coupling. Proc Natl Acad Sci USA 2008; 105: 1073-1078. (Pubitemid 351282083)
28. Matsui T, Mori T, Tateishi N, Kagamiishi Y, Satoh S, Katsube N et al. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part I: enhanced astrocytic synthesis of s-100beta in the periinfarct area precedes delayed infarct expansion. J Cereb Blood Flow Metab 2002; 22: 711-722. (Pubitemid 34596464)
29. Liu F, Schafer DP, McCullough LD. Ttc, fluoro-jade b and neun staining confirm evolving phases of infarction induced by middle cerebral artery occlusion. J Neurosci Methods 2009; 179: 1-8.
30. Du C, Hu R, Csernansky CA, Hsu CY, Choi DW. Very delayed infarction after mild focal cerebral ischemia: a role for apoptosis? J Cereb Blood Flow Metab 1996; 16: 195-201. (Pubitemid 26062810)
31. Sutherland BA, Papadakis M, Chen RL, Buchan AM. Cerebral blood flow alteration in neuroprotection following cerebral ischaemia. J Physiol 2011; 589: 4105-4114.
32. Dijkhuizen RM, Beekwilder JP, van der Worp HB, Berkelbach van der Sprenkel JW, Tulleken KA, Nicolay K. Correlation between tissue depolarizations and damage in focal ischemic rat brain. Brain Res 1999; 840: 194-205. (Pubitemid 29434843)